Literature DB >> 20952768

Influence of cardiomegaly on disordered breathing during exercise in chronic heart failure.

Thomas P Olson1, Bruce D Johnson.   

Abstract

AIMS: Heart failure (HF) patients breathe with a rapid shallow pattern during exercise. This study examined the relationship between cardiac size and tachypnoeic breathing in HF patients during exercise. METHODS AND
RESULTS: Thirty-seven HF patients [age = 55 ± 13 years, ejection fraction (EF) = 27 ± 10%, New York Heart Association (NYHA) class = 2.3 ± 1.2] and 42 controls (CTL) (age = 56 ± 14 years, EF = 63 ± 8%) were recruited. Participants underwent maximal exercise testing, pulmonary function testing, and chest radiography for calculation of total thoracic cavity volume (TTCV), diaphragm, heart, and lung volumes. Heart failure patients were divided into two groups: Group A = cardiac volume < median (n = 18) and Group B = cardiac volume ≥ median of the HF patients (n = 19). There was no difference between groups for TTCV (CTL = 8203 ± 1489 vs. Group A = 8694 ± 1249 vs. Group B = 8195 ± 1823 cm(3)). Cardiac volume was different between groups for both absolute (CTL = 630 ± 181 vs. Group A = 894 ± 186 vs. Group B = 1401 ± 382 cm(3), P< 0.001 for all comparisons) and %TTCV (CTL = 8 ± 2 vs. Group A = 10 ± 1 vs. Group A = 18 ± 5%, P< 0.001 for all comparisons). Similarly, total lung volume as a %TTCV was significantly different among the groups (CTL = 70 ± 4 vs. Group A = 65 ± 5 vs. Group A = 58 ± 7%, P< 0.01 for all comparisons). In HF patients, there was a trend (P = 0.10) towards an independent association between cardiac size and tidal volume (V(T)) at 75% of VO(2) peak whereas this relationship was statistically significant at VO(2) peak (P = 0.02) as patients with larger cardiac size had reduced V(T).
CONCLUSION: This study demonstrates the close relationship between cardiac size and breathing pattern during exercise in HF patients. These results suggest cardiac size may pose a significant constraint on the lungs during exercise and may contribute to tachypnoeic breathing.

Entities:  

Mesh:

Year:  2010        PMID: 20952768      PMCID: PMC3041466          DOI: 10.1093/eurjhf/hfq177

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  34 in total

1.  Response of slowly adapting pulmonary stretch receptors to reduced lung compliance.

Authors:  J Yu; T E Pisarri; J C Coleridge; H M Coleridge
Journal:  J Appl Physiol (1985)       Date:  1991-08

2.  Single breath carbon monoxide diffusing capacity (transfer factor). Recommendations for a standard technique. Statement of the American Thoracic Society.

Authors: 
Journal:  Am Rev Respir Dis       Date:  1987-11

3.  Mechanism of stimulation of type J pulmonary receptors.

Authors:  A S Paintal
Journal:  J Physiol       Date:  1969-08       Impact factor: 5.182

4.  Cardiac mensuration by the cardiac volume method.

Authors:  T E Keats; I P Enge
Journal:  Radiology       Date:  1965-11       Impact factor: 11.105

5.  Respiratory muscle strength in congestive heart failure.

Authors:  M D Hammond; K A Bauer; J T Sharp; R D Rocha
Journal:  Chest       Date:  1990-11       Impact factor: 9.410

6.  Ventilatory and diffusion abnormalities in potential heart transplant recipients.

Authors:  R S Wright; M S Levine; P E Bellamy; M S Simmons; P Batra; L W Stevenson; J A Walden; H Laks; D P Tashkin
Journal:  Chest       Date:  1990-10       Impact factor: 9.410

7.  Bronchial hyperresponsiveness to methacholine in patients with impaired left ventricular function.

Authors:  L R Cabanes; S N Weber; R Matran; J Regnard; M O Richard; M E Degeorges; A Lockhart
Journal:  N Engl J Med       Date:  1989-05-18       Impact factor: 91.245

8.  Heart failure and airway obstruction.

Authors:  W Petermann; J Barth; P Entzian
Journal:  Int J Cardiol       Date:  1987-11       Impact factor: 4.164

9.  Abnormal pulmonary function specifically related to congestive heart failure: comparison of patients before and after cardiac transplantation.

Authors:  J D Hosenpud; T A Stibolt; K Atwal; D Shelley
Journal:  Am J Med       Date:  1990-05       Impact factor: 4.965

10.  Serial pulmonary function in patients with acute heart failure.

Authors:  R W Light; R B George
Journal:  Arch Intern Med       Date:  1983-03
View more
  7 in total

Review 1.  Obstructive Ventilatory Disorder in Heart Failure-Caused by the Heart or the Lung?

Authors:  Sergio Caravita; Jean-Luc Vachiéry
Journal:  Curr Heart Fail Rep       Date:  2016-12

2.  Submaximal Exercise Pulmonary Gas Exchange in Left Heart Disease Patients With Different Forms of Pulmonary Hypertension.

Authors:  Bryan J Taylor; Michael R Smetana; Robert P Frantz; Bruce D Johnson
Journal:  J Card Fail       Date:  2015-04-14       Impact factor: 5.712

3.  Use of 'ideal' alveolar air equations and corrected end-tidal PCO2 to estimate arterial PCO2 and physiological dead space during exercise in patients with heart failure.

Authors:  Erik H Van Iterson; Thomas P Olson
Journal:  Int J Cardiol       Date:  2017-10-07       Impact factor: 4.164

4.  Algorithm for Predicting Disease Likelihood From a Submaximal Exercise Test.

Authors:  Chul-Ho Kim; James E Hansen; Dean J MacCarter; Bruce D Johnson
Journal:  Clin Med Insights Circ Respir Pulm Med       Date:  2017-07-13

5.  The clinical associations with cardiomegaly in patients undergoing evaluation for pulmonary hypertension.

Authors:  Benjamin Daines; Sanjana Rao; Omid Hosseini; Sofia Prieto; John Abdelmalek; Mohamed Elmassry; Pooja Sethi; Victor Test; Kenneth Nugent
Journal:  J Community Hosp Intern Med Perspect       Date:  2021-11-15

6.  Ventilatory constraints influence physiological dead space in heart failure.

Authors:  Joshua R Smith; Thomas P Olson
Journal:  Exp Physiol       Date:  2018-11-23       Impact factor: 2.969

7.  Streamlining cardiopulmonary exercise testing for use as a screening and tracking tool in primary care.

Authors:  Chul-Ho Kim; Erik H Van Iterson; James E Hansen; Dean J MacCarter; Bruce D Johnson
Journal:  Pulm Circ       Date:  2018-04-25       Impact factor: 3.017

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.